NDAINJECTIONINJECTABLE
Approved
Nov 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
BRETHINE (terbutaline sulfate) by Aspen Pharmacare is clinical pharmacology in vitro and in vivo pharmacologic studies have demonstrated that terbutaline exerts a preferential effect on beta 2 -adrenergic receptors. First approved in 1981.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Brethine (terbutaline sulfate) is a beta-2 adrenergic agonist administered by injection for acute bronchospasm relief in patients with obstructive airway disease. It works by stimulating beta-2 receptors on bronchial smooth muscle, increasing intracellular cAMP and causing bronchodilation with measurable effects within 30 minutes and maximum effect within 2–3 hours.
LOE Approaching
Approaching loss of exclusivity signals likely team downsizing and shift toward generic transition management rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY In vitro and in vivo pharmacologic studies have demonstrated that terbutaline exerts a preferential effect on beta 2 -adrenergic receptors. While it is recognized that beta2-adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there…
Worked on BRETHINE at Aspen Pharmacare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.